ISB News

Promotion: Michael Hoopmann Becomes Senior Research Scientist

Congratulations to Dr. Michael Hoopmann, of the Moritz Lab, who has been promoted to Senior Research Scientist. His research is focused on proteomics technology and methods development, having been trained in both instrumentation and software data analysis, with particular focus on high-resolution mass spectrometry. His current interests are in the development of advanced algorithms for discovery-based proteomics. He is the developer of the Kojak algorithm, a versatile, open-source software application for the discovery of protein-protein interactions through shotgun-based mass spectrometry. Dr. Hoopmann is also a contributor to the Trans-Proteomic Pipeline suite of software solutions for mass spectrometry data analysis.

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.